G01N33/94

Method for detecting methimazole by surface-enhanced raman scattering

A method for analyzing or detecting methimazole (“MTZ”) comprising contacting a sample suspected of containing MTZ with the dendrimer-stabilized silver nanoparticles and performing surface-enhanced Raman scattering (SERS). Graphene-dendrimer-stabilized silver nanoparticles (G-D-Ag).

Test strip and kit for testing mycophenolic acid and preparation method of test strip

A test strip and kit for testing mycophenolic acid and a preparation method of the test strip are described. The test strip includes a bottom plate and a sample pad, a glassfiber membrane, a nitrocellulose membrane and an absorbent paper which are successively lapped on a surface of the bottom plate, the sample pad is treated by a sample pad treatment fluid; the glassfiber membrane is treated by a glassfiber membrane treatment fluid; the glassfiber membrane is coated by a mycophenolic acid specific-antibody conjugate; the nitrocellulose membrane is provided with a detection line and a quality control line; and a mycophenolic acid protein conjugate is sprayed on the detection line.

Arylalkylamine, pyrrole, indole, and opiate derivative concentration determination method and test kit using said method
20230067029 · 2023-03-02 ·

The invention relates to an arylalkylamine, pyrrole, indole and opiate derivative concentration determination method and a test kit using said method for precise determination of the presence and precise concentration of said substances which have an indole as a structural element and similarly structured substances having primary amines or pyrrole compounds, phenylethylamines and other substances. The problem addressed by the invention of is that of providing an arylalkylamine, pyrrole, indole and opiate derivative concentration determination method and a test kit for concentration determination, which provide fast, low-cost and low-effort quantitative detection of indole derivatives, in particular of psilocybin, and of arylalkylamine, pyrrole or opiate derivatives and in so doing enable precise determination of the presence and precise concentrations of different natural substances, such as psilocybin, for example, which have an indole as a structural fragment, and similarly structured substances having primary or secondary amines or pyrrole compounds in a rapid test. Said problem is solved in that the method comprises two method steps in the form of an extraction step and a subsequent analysis step using a color reagent, wherein in the analysis step at least one color reagent having at least one arylalkyl, pyrrole, indole or opiate derivative causes a quantitative and linear color reaction which is measurable by means of colorimetric methods and which is detected and evaluated.

SYSTEMS, METHODS, AND COMPOSITIONS TO IDENTIFY NEW PROTEIN TARGETS OF A CHEMICAL COMPOUND OR ITS DERIVATIVES
20230118154 · 2023-04-20 ·

Systems and methods to identify new protein targets of a chemical compound or its derivatives were described. The methods can be used for detection of new binding partners as long as the chemical compound can covalently bind to the protein targets. Once protein targets are resolved, information related to new protein targets can then be used to couple with real-world patient data such as adverse events, efficacy data, and disease correlation data to deduce real-world evidence. Systems collectively with all this information can aide clinical development and use of pharmaceutical drug. Methods are provided for detection of covalently bound phenyl vinyl sulfone (PVS) or its derivatives, and afatinib or its derivatives. Furthermore, generation of antiserum recognizing carrier bound PVS or carrier bound afatinib is described. PRMT1 is described as a new target of PVS and RRM1, RRM2, and NFKB are described as new targets of afatinib.

6-acetylmorphine analogs, and methods for their synthesis and use

The present invention relates to novel 6-acetylmorphine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.

Diagnostic test for distinguishing the smoking status of a subject

There is disclosed herein a device for determining the smoking status of a subject, wherein said device comprises a plurality of different specific binding molecules deposited to a solid phase to detect specifically the presence of two or three tobacco smoke exposure biomarkers in a biological sample, said biomarkers consisting of: (i) cotinine and total 4-(methylnitrosamino)-1-(3-, pyridyl)-1-butanol (NNAL); (ii) cotinine and N-acetyl-S-[2-carboxyethyl]-L-cysteine (CEMA); or (iii) cotinine and NNAL and CEMA.

Diagnostic test for distinguishing the smoking status of a subject

There is disclosed herein a device for determining the smoking status of a subject, wherein said device comprises a plurality of different specific binding molecules deposited to a solid phase to detect specifically the presence of two or three tobacco smoke exposure biomarkers in a biological sample, said biomarkers consisting of: (i) cotinine and total 4-(methylnitrosamino)-1-(3-, pyridyl)-1-butanol (NNAL); (ii) cotinine and N-acetyl-S-[2-carboxyethyl]-L-cysteine (CEMA); or (iii) cotinine and NNAL and CEMA.

Method of inhibiting tau phosphorylation

A method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.

Method of inhibiting tau phosphorylation

A method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.

Compositions and methods for blood storage

The present disclosure relates to compositions and methods for determining the quality of stored blood and detecting Autologous Blood Transfusions (ABT) and blood doping.